Immunotherapy for triple-negative breast cancer: current trends and future prospects

被引：0

作者：

Essalihi, Amina ^{[1
]}

Bouchra, Oumaima ^{[1
]}

Khadiri, Khadija ^{[2
]}

Khadrouf, Zineb ^{[2
]}

Karkouri, Mehdi ^{[1
,3
]}

机构：

[1] Hassan II Univ Casablanca, Fac Med & Pharm, Lab Cellular & Mol Pathol, Casablanca, Morocco

[2] Hassan II Univ Casablanca, Fac Sci Ain Chock, Lab Immunol & Biodivers, Casablanca, Morocco

[3] Univ Hosp Ibn Rochd, Pathol Dept, Casablanca, Morocco

来源：

JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE | 2025年 / 37卷 / 01期

关键词：

Immunotherapy; Triple-negative breast cancer; Immune checkpoint inhibitors; Clinical Trials; PDL-1; Tumor-infiltrating lymphocytes; PEMBROLIZUMAB PLUS CHEMOTHERAPY; OPEN-LABEL; DOUBLE-BLIND; EARLY-STAGE; HIGH-RISK; ATEZOLIZUMAB; KEYNOTE-355; PACLITAXEL; TRIAL;

D O I：

10.1186/s43046-025-00295-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) accounts for 10-20% of all breast cancers. These tumors are heterogeneous, highly aggressive, and associated with a poor prognosis and a high risk of recurrence. In both hematologic and solid malignancies, immune checkpoint inhibitors (ICIs) have demonstrated the ability to enhance long-term survival and sustain robust anti-tumor responses. Immunotherapy has also been introduced as a treatment option for TNBC, a subtype characterized by a high presence of intra-tumoral tumor-infiltrating lymphocytes (TILs) and stromal immune cells. This heightened immune activity within TNBC serves as a prognostic marker, indicating a potential for better responses to immunotherapy due to increased tumor immune infiltration. This review provides an overview of the current landscape of immunotherapy in TNBC, exploring its rationale and application across different disease stages. Trial registration NCT02555657.

引用

页数：10

共 63 条

[1] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[2] Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer [J].

Agostinetto, Elisa ;

Losurdo, Agnese ;

Nader-Marta, Guilherme ;

Santoro, Armando ;

Punie, Kevin ;

Barroso, Romualdo ;

Popovic, Lazar ;

Solinas, Cinzia ;

Kok, Marleen ;

de Azambuja, Evandro ;

Lambertini, Matteo .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) :567-591

[3]

Author T, 2018, Behalf of the European Society for Medical Oncology

[4] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial [J].

Bachelot, Thomas ;

Filleron, Thomas ;

Bieche, Ivan ;

Arnedos, Monica ;

Campone, Mario ;

Dalenc, Florence ;

Coussy, Florence ;

Sablin, Marie-Paule ;

Debled, Marc ;

Lefeuvre-Plesse, Claudia ;

Goncalves, Anthony ;

Reynier, Marie-Ange Mouret ;

Jacot, William ;

You, Benoit ;

Barthelemy, Philippe ;

Verret, Benjamin ;

Isambert, Nicolas ;

Tchiknavorian, Xavier ;

Levy, Christelle ;

Thery, Jean-Christophe ;

L'Haridon, Tifenn ;

Ferrero, Jean-Marc ;

Mege, Alice ;

Del Piano, Francesco ;

Rouleau, Etienne ;

Tran-Dien, Alicia ;

Adam, Julien ;

Lusque, Amelie ;

Jimenez, Marta ;

Jacquet, Alexandra ;

Garberis, Ingrid ;

Andre, Fabrice .

NATURE MEDICINE, 2021, 27 (02) :250-+

[5] Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130 [J].

Badve, Sunil S. ;

Penault-Llorca, Frederique ;

Reis-Filho, Jorge S. ;

Deurloo, Regula ;

Siziopikou, Kalliopi P. ;

D'Arrigo, Corrado ;

Viale, Giuseppe .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (05) :664-675

[6] Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial [J].

Bianchini, G. ;

Huang, C-S. ;

Egle, D. ;

Bermejo, B. ;

Zamagni, C. ;

Thill, M. ;

Anton, A. ;

Zambelli, S. ;

Russo, S. ;

Ciruelos, E. M. ;

Greil, R. ;

Semiglazov, V. ;

Colleoni, M. A. ;

Kelly, C. M. ;

Mariani, G. ;

Del Mastro, L. ;

Smart, C. ;

Valagussa, P. ;

Viale, G. ;

Gianni, L. .

ANNALS OF ONCOLOGY, 2020, 31 :S1145-S1146

[7] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis [J].

Brufsky, A. ;

Kim, S. B. ;

Zvirbule, Z. ;

Eniu, A. ;

Mebis, J. ;

Sohn, J. H. ;

Wongchenko, M. ;

Chohan, S. ;

Amin, R. ;

Yan, Y. ;

McNally, V ;

Miles, D. ;

Loi, S. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :652-660

[8]

Cai LT, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01499-1

[9] Immunotherapy in breast cancer: A clinician's perspective [J].

Chaudhuri, Sibapriya ;

Thomas, Scott ;

Munster, Pamela .

JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (02) :47-57

[10] Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies [J].

Cilibrasi, Chiara ;

Papanastasopoulos, Panagiotis ;

Samuels, Mark ;

Giamas, Georgios .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21) :23-45

← 1 2 3 4 5 6 7 →